Analyst Price Target is $50.20
▲ +72.87% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Amylyx Pharmaceuticals in the last 3 months. The average price target is $50.20, with a high forecast of $54.00 and a low forecast of $47.00. The average price target represents a 72.87% upside from the last price of $29.04.
Current Consensus is
The current consensus among 5 contributing investment analysts is to buy stock in Amylyx Pharmaceuticals.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.